Long-term safety follow-up for people treated with A2 Bio gene therapy products
Follows adults who received A2 Bio gene therapy for cancers, watching for late safety problems.
Plain-language title generated from the registry record
Registry title: A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
Key facts
- Where
- Gilbert, New York, and Rochester, United StatesSee the 3 sites
Where in United States
- Banner HealthGilbert, United StatesNo longer taking part
- NYU Langone Medical CenterNew York, United StatesNo longer taking part
- Mayo ClinicRochester, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- A2 Biotherapeutics Inc.
- Trial code
- NCT06885424
- Record updated
- 20 May 2026
- Original description
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.Read full original descriptionShow less
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2Bio) Gene Therapy (GT) Products
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Inclusion: Received any amount of A2 Bio GT product on a previous A2 Bio interventional study; Able to provide written informed consent for this long-term follow-up study; Able to comply with study requirements.
Exclusion: There are no specific exclusion criteria for this study.